{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:54:02Z","timestamp":1715943242957},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T00:00:00Z","timestamp":1284681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T00:00:00Z","timestamp":1284681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/cgt.2010.50","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T10:19:40Z","timestamp":1284718780000},"page":"34-41","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma"],"prefix":"10.1038","volume":"18","author":[{"given":"X","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W T","family":"Godbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,17]]},"reference":[{"key":"BFcgt201050_CR1","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","volume":"25","author":"Z Shen","year":"2008","unstructured":"Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL . Intravesical treatments of bladder cancer: review. Pharm Res 2008; 25: 1500\u20131510.","journal-title":"Pharm Res"},{"key":"BFcgt201050_CR2","first-page":"97","volume":"9","author":"R Pearl","year":"1929","unstructured":"Pearl R . Cancer and tuberculosis. Am J Hyg 1929; 9: 97\u2013159.","journal-title":"Am J Hyg"},{"key":"BFcgt201050_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1015-9584(08)60045-7","volume":"30","author":"AH Razack","year":"2007","unstructured":"Razack AH . Bacillus Calmette-Guerin and bladder cancer. Asian J Sur 2007; 30: 302\u2013309.","journal-title":"Asian J Sur"},{"key":"BFcgt201050_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891\u2013899.","journal-title":"N Engl J Med"},{"key":"BFcgt201050_CR5","first-page":"409","volume":"58","author":"T Kawamori","year":"1998","unstructured":"Kawamori T, Rao CV, Seibert K, Reddy BS . Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409\u2013412.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR6","first-page":"293","volume":"60","author":"BS Reddy","year":"2000","unstructured":"Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293\u2013297.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR7","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","volume":"21","author":"NK Altorki","year":"2003","unstructured":"Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21: 2645\u20132650.","journal-title":"J Clin Oncol"},{"key":"BFcgt201050_CR8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0022-5223(03)00790-6","volume":"126","author":"CA Diperna","year":"2003","unstructured":"Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, Bremner RM . Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 2003; 126: 1129\u20131133.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"BFcgt201050_CR9","first-page":"S103","volume":"26","author":"W Liu","year":"2003","unstructured":"Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003; 26: S103\u2013S109.","journal-title":"Am J Clin Oncol"},{"key":"BFcgt201050_CR10","first-page":"1377","volume":"7","author":"GA Alshafie","year":"2000","unstructured":"Alshafie GA, Abou-Issa HM, Seibert K, Harris RE . Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7: 1377\u20131381.","journal-title":"Oncol Rep"},{"key":"BFcgt201050_CR11","first-page":"2101","volume":"60","author":"RE Harris","year":"2000","unstructured":"Harris RE, Alshafie GA, Abou-Issa H, Seibert K . Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101\u20132103.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR12","first-page":"2343","volume":"62","author":"N Kundu","year":"2002","unstructured":"Kundu N, Fulton AM . Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343\u20132346.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR13","doi-asserted-by":"publisher","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","volume":"275","author":"AL Hsu","year":"2000","unstructured":"Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS . The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397\u201311403.","journal-title":"J Biol Chem"},{"key":"BFcgt201050_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-04-1877","volume":"11","author":"MI Patel","year":"2005","unstructured":"Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999\u20132007.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201050_CR15","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3748\/wjg.v10.i13.1971","volume":"10","author":"SL Fu","year":"2004","unstructured":"Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y . Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004; 10: 1971\u20131974.","journal-title":"World J Gastroenterol"},{"key":"BFcgt201050_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/1535-7163.MCT-07-0313","volume":"7","author":"D Dhawan","year":"2008","unstructured":"Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW . Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008; 7: 897\u2013904.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201050_CR17","first-page":"5599","volume":"60","author":"CJ Grubbs","year":"2000","unstructured":"Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599\u20135602.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","volume":"353","author":"CJ Hawkey","year":"1999","unstructured":"Hawkey CJ . COX-2 inhibitors. Lancet 1999; 353: 307\u2013314.","journal-title":"Lancet"},{"key":"BFcgt201050_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885\u2013895.","journal-title":"N Engl J Med"},{"key":"BFcgt201050_CR20","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","volume":"114","author":"SD Solomon","year":"2006","unstructured":"Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028\u20131035.","journal-title":"Circulation"},{"key":"BFcgt201050_CR21","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.2003.09.138","volume":"21","author":"LC Pagliaro","year":"2003","unstructured":"Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003; 21: 2247\u20132253.","journal-title":"J Clin Oncol"},{"key":"BFcgt201050_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1200\/JCO.2002.20.4.957","volume":"20","author":"J Kuball","year":"2002","unstructured":"Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20: 957\u2013965.","journal-title":"J Clin Oncol"},{"key":"BFcgt201050_CR23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","volume":"16","author":"PU Malmstr\u00f6m","year":"2010","unstructured":"Malmstr\u00f6m PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A et al. AdCD40L immunogene therapy for bladder carcinoma\u2013the first phase I\/IIa trial. Clin Cancer Res 2010; 16: 3279\u20133787.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201050_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/sj.gt.3302012","volume":"10","author":"WT Godbey","year":"2003","unstructured":"Godbey WT, Atala A . Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene ther 2003; 10: 1519\u20131527.","journal-title":"Gene ther"},{"key":"BFcgt201050_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/cgt.2008.7","volume":"15","author":"X Zhang","year":"2008","unstructured":"Zhang X, Atala A, Godbey WT . Expression-targeted gene therapy for the treatment of transitional cell carcinoma. Cancer Gene Ther 2008; 15: 543\u2013552.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201050_CR26","first-page":"5647","volume":"59","author":"SI Mohammed","year":"1999","unstructured":"Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647\u20135650.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1541-7786.632.2.11","volume":"2","author":"GD Basu","year":"2004","unstructured":"Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P . Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004; 2: 632\u2013642.","journal-title":"Mol Cancer Res"},{"key":"BFcgt201050_CR28","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1158\/0008-5472.CAN-06-0992","volume":"66","author":"AM Carothers","year":"2006","unstructured":"Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM . Changes in antitumor response in C57BL\/6J-Min\/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 2006; 66: 6432\u20136438.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR29","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1158\/0008-5472.CAN-03-2422","volume":"64","author":"S Gupta","year":"2004","unstructured":"Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334\u20133343.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR30","first-page":"3843","volume":"50","author":"MA Hudson","year":"1990","unstructured":"Hudson MA, Ritchey JK, Catalona WJ, Brown EJ, Ratliff TL . Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 1990; 50: 3843\u20133847.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12033-008-9133-9","volume":"41","author":"X Zhang","year":"2009","unstructured":"Zhang X, Turner C, Godbey WT . Comparison of caspase genes for the induction of apoptosis following gene delivery. Mol Biotechnol 2009; 41: 236\u2013246.","journal-title":"Mol Biotechnol"},{"key":"BFcgt201050_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180\u2013183.","journal-title":"J Urol"},{"key":"BFcgt201050_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0094-0143(21)00421-3","volume":"19","author":"A Morales","year":"1992","unstructured":"Morales A, Nickel JC . Immunotherapy for superficial bladder cancer. A developmental and clinical overview. Urol Clin N Am 1992; 19: 549\u2013556.","journal-title":"Urol Clin N Am"},{"key":"BFcgt201050_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1055-3207(18)30447-2","volume":"4","author":"MA O'Donnell","year":"1995","unstructured":"O'Donnell MA, DeWolf WC . Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995; 4: 189\u2013202.","journal-title":"Surg Oncol Clin N Am"},{"issue":"Suppl 2","key":"BFcgt201050_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000474916","volume":"21","author":"TL Ratliff","year":"1992","unstructured":"Ratliff TL . Role of the immune response in BCG for bladder cancer. Eur Urol 1992; 21 (Suppl 2): 17\u201321.","journal-title":"Eur Urol"},{"key":"BFcgt201050_CR36","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0022-5347(17)32567-3","volume":"152","author":"DL Cheng","year":"1994","unstructured":"Cheng DL, Shu WP, Choi JC, Margolis EJ, Droller MJ, Liu BC . Bacillus Calmette-Guerin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol 1994; 152: 1275\u20131280.","journal-title":"J Urol"},{"key":"BFcgt201050_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL . Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990; 85: 62\u201367.","journal-title":"J Clin Invest"},{"key":"BFcgt201050_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","volume":"145","author":"MJ Becich","year":"1991","unstructured":"Becich MJ, Carroll S, Ratliff TL . Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol 1991; 145: 1316\u20131324.","journal-title":"J Urol"},{"key":"BFcgt201050_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1172\/JCI116202","volume":"91","author":"K Kuroda","year":"1993","unstructured":"Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL . Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993; 91: 69\u201376.","journal-title":"J Clin Invest"},{"key":"BFcgt201050_CR40","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF . Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 1636\u20131642.","journal-title":"J Urol"},{"key":"BFcgt201050_CR41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/262584a0","volume":"262","author":"SA Wolfe","year":"1976","unstructured":"Wolfe SA, Tracey DE, Henney CS . Introduction of \u2018natural\u2019 killer' cells by BCG. Nature 1976; 262: 584\u2013586.","journal-title":"Nature"},{"key":"BFcgt201050_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/384644a0","volume":"384","author":"RG Kurumbail","year":"1996","unstructured":"Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644\u2013648.","journal-title":"Nature"},{"key":"BFcgt201050_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.1376","volume":"93","author":"GR Jerry","year":"2001","unstructured":"Jerry GR, Chandan C, Peeyush KL . Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497\u2013506.","journal-title":"Int J Cancer"},{"key":"BFcgt201050_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","volume":"93","author":"M Tsujii","year":"1998","unstructured":"Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705\u2013716.","journal-title":"Cell"},{"key":"BFcgt201050_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/mp060001j","volume":"3","author":"P Tyagi","year":"2006","unstructured":"Tyagi P, Wu P-C, Chancellor M, Yoshimura N, Huang L . Recent advances in intravesical drug\/gene delivery. Mol Pharm 2006; 3: 369\u2013379.","journal-title":"Mol Pharm"},{"key":"BFcgt201050_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","volume":"91","author":"RF Bevers","year":"2004","unstructured":"Bevers RF, Kurth KH, Schamhart DH . Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91: 607\u2013612.","journal-title":"Br J Cancer"},{"key":"BFcgt201050_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2007-1001917","volume":"20","author":"DH Schamhart","year":"1994","unstructured":"Schamhart DH, De Boer EC, Vleeming R, Kurth KH . Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer. Semin Thromb Hemost 1994; 20: 301\u2013309.","journal-title":"Semin Thromb Hemost"},{"key":"BFcgt201050_CR48","first-page":"1762","volume":"47","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Palmer JO, McGarr JA, Brown EJ . Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 1987; 47: 1762\u20131766.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR49","first-page":"2834","volume":"59","author":"JH Gunther","year":"1999","unstructured":"Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999; 59: 2834\u20132837.","journal-title":"Cancer Res"},{"key":"BFcgt201050_CR50","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/sj.gt.3300976","volume":"6","author":"WT Godbey","year":"1999","unstructured":"Godbey WT, Wu KK, Hirasaki GJ, Mikos AG . Improved packing of poly(ethylenimine)\/DNA complexes increases transfection efficiency. Gene Ther 1999; 6: 1380\u20131388.","journal-title":"Gene Ther"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201050","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T10:52:02Z","timestamp":1685789522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFcgt201050"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2010.50","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,17]]},"assertion":[{"value":"26 December 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}